You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Remsima

Showing 1 - 25 of 33
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Psoriasis Trial in Lahore (Remsima)

Completed
  • Psoriasis
  • Remsima
  • Lahore, Punjab, Pakistan
    Ghurki Hospital
Sep 12, 2023

Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis Trial in Toulouse (Remsima IV, Remsima SC)

Recruiting
  • Rheumatoid Arthritis
  • +3 more
  • Remsima IV
  • Remsima SC
  • Toulouse, France
    CHU Purpan Hôpital Pierre Paul Riquet
May 17, 2023

IBD Trial in Paris (Biocollection)

Not yet recruiting
  • Inflammatory Bowel Diseases
  • Biocollection
  • Paris, France
    Saint Antoine Hospital Service de Gastroentérologie et Nutrition
Feb 1, 2023

A 24-month Real Life PErsistence Efficacy and Safety Study in

Recruiting
  • Inflammatory Bowel Diseases
  • Subcutaneous infliximab CT-P13 Remsima®SC
  • Grenoble, France
    Nicolas Mathieu
Aug 2, 2022

Hidradenitis Suppurativa Trial in Lahore (Infliximab biosimilar)

Active, not recruiting
  • Hidradenitis Suppurativa
  • Infliximab biosimilar
  • Lahore, Punjab, Pakistan
    Services Institute of Medical Sciences
Dec 22, 2022

Crohn's Disease, Ulcerative Colitis Trial

Terminated
Has Results
  • Crohn's Disease
  • Ulcerative Colitis
    • (no location specified)
    Dec 6, 2021

    Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

    Not yet recruiting
    • Rheumatoid Arthritis
    • +2 more
    • collection of clinical parameters and blood sample
    • Paris, IDF, France
      Rheumatology Department, Cochin Hospital
    Jun 17, 2022

    Crohn Disease Trial (Azathioprine + infliximab, Intestinal resection)

    Not yet recruiting
    • Crohn Disease
    • Azathioprine + infliximab
    • Intestinal resection
    • (no location specified)
    Oct 14, 2022

    Inflammatory Disease, Disease Crohn, Bowel Disease Trial in Amsterdam (Infliximab subcutaneous, Immunosuppressive Agents)

    Recruiting
    • Inflammatory Disease
    • +2 more
    • Infliximab subcutaneous
    • Immunosuppressive Agents
    • Amsterdam, North Holland, Netherlands
      Amsterdam UMC AMC
    Sep 27, 2023

    Colitis, Ulcerative Trial in Amsterdam (Infliximab)

    Recruiting
    • Colitis, Ulcerative
    • Dublin, Ireland
    • +6 more
    Dec 2, 2022

    Crohn Disease Trial in Paris (Infliximab CT-P13, Immunosuppressors (Thiopurines or Methotrexate))

    Recruiting
    • Crohn Disease
    • Infliximab CT-P13
    • Immunosuppressors (Thiopurines or Methotrexate)
    • Paris, France
      GETAID
    Aug 2, 2022

    Multisystem Inflammatory Syndrome-Children Trial in San Diego, Detroit (Infliximab, Anakinra, Methylprednisolone)

    Recruiting
    • Multisystem Inflammatory Syndrome-Children
    • San Diego, California
    • +1 more
    Mar 28, 2022

    Colitis,Ulcerative Trial in Norway (Discontinuation of anti-TNF treatment, Continuation of anti-TNF treatment)

    Active, not recruiting
    • Colitis,Ulcerative
    • Discontinuation of anti-TNF treatment
    • Continuation of anti-TNF treatment
    • Alesund, Norway
    • +18 more
    Jul 13, 2022

    Tumor Necrosis Factor-alpha Antagonists in Rheumatoid Arthritis.

    Recruiting
    • Rheumatoid Arthritis
    • +2 more
    • Infliximab: Adalimumab; Etanercept;
    • Sulaymaniyah, Kurdistan Region, Iraq
      Hiwa Khidhir Saaed
    May 12, 2022

    Ankylosing Spondylitis, Axial Spondyloarthritis Trial (Adalimumab and its biosimilars, Biological: Etanercept and its

    Not yet recruiting
    • Ankylosing Spondylitis
    • Axial Spondyloarthritis
    • Adalimumab and its biosimilars
    • +3 more
    • (no location specified)
    Dec 6, 2021

    Post-Operative Crohn's Disease Outcome in Children

    Recruiting
    • Crohn Disease
    • Petach Tikva, Israel
      Schneider Children's Hospital
    Sep 25, 2021

    IBD, Crohn Disease, Colitis, Ulcerative Trial in Belgium, Netherlands, Spain (Infliximab, Adalimumab)

    Recruiting
    • Inflammatory Bowel Diseases
    • +2 more
    • Infliximab
    • Adalimumab
    • Gent, Belgium
    • +6 more
    May 17, 2022

    Remsima® in Treatment of Inflammatory Bowel Diseases Among Saudi

    Completed
    • Inflammatory Bowel Diseases
    • +3 more
    • Jeddah, Saudi Arabia
    • +3 more
    Feb 22, 2021

    Real-World Emulation of the SWEFOT Trial

    Completed
    • Rheumatoid Arthritis
    • Infliximab
    • Sulfasalazine + Hydroxychloroquine
    • Stockholm, Sweden
      Karolinska Institutet, Department of Medicine Solna, Clinical Ep
    Sep 22, 2021

    Crohn's Disease Trial in Seoul (Infliximab-Dyyb)

    Not yet recruiting
    • Crohn's Disease
    • Seoul, Korea, Republic of
      Asan Medical Center
    Oct 5, 2023

    Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

    Completed
    • Rheumatoid Arthritis
    • Biosimilar Infliximab
    • Amman, Jordan
    • +1 more
    Mar 3, 2020

    Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma

    Recruiting
    • Clinical Stage 0 Cutaneous Melanoma AJCC v8
    • +43 more
    • Best Practice
    • +7 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 12, 2022

    Infusion Related Reactions in Patients Receiving Infliximab

    Active, not recruiting
    • Chronic Inflammatory Disease
      • Bergen, Norway
        Haukeland University Hospital
      Jun 15, 2021

      Subcutaneous Infliximab Levels.

      Completed
      • Inflammatory Bowel Diseases
        • Sevilla, Spain
          Hospital Universitario Virgen Macarena
        Nov 15, 2021

        Theranostic Test to PREDict Treatment Response of Anti-TNFa

        Terminated
        • RheumatoId Arthritis
        • Infliximab
        • +6 more
        • Prague, Czechia
        • +7 more
        Dec 21, 2019